Tilos Therapeutics

Tilos Therapeutics Overview

Founded 2016
Founded
Status Acquired/​Merged
Latest Deal Type M&A
Latest Deal Amount $773M
Latest Deal Amount

Tilos Therapeutics General Information

Description

Developer of antibody therapeutics designed to treat cancer, fibrosis and related disorders. The company's antibody therapeutics harnesses the power of the immune system to develop new therapies that target key immunological pathways with a primary focus on regulatory T cells and regulation of effector cells, enabling patients to start treatment more quickly, resulting in a better medical outcome.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Parent Company
Primary Office
  • 65 Hayden Avenue
  • Lexington, MA 02421
  • United States
+1 (781) 000-0000

Tilos Therapeutics Timeline

201720182019
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tilos Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 01-Jun-2019 $773M 00.00 00000 Completed Startup
2. Seed Round 21-Sep-2017 00.000 00.00 00.000 Completed Startup
1. Seed Round 30-Aug-2016 $750K $750K 00.000 Completed Startup

Tilos Therapeutics Cap Table

To view Tilos Therapeutics‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 0,000,000 00.000000 00 00 00 00 00 00.000

Tilos Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Jessie English Ph.D Chief Scientific Officer
John Edwards Executive Chairman & Board Member

1 Former Executive

Tilos Therapeutics Board Members (8)

To view Tilos Therapeutics‘s full board member team, request access »
Name Representing Role Since
Detlev Biniszkiewicz Ph.D Self Board Member 000 0000
James Kasuboski Ph.D Self Board Member 000 0000
John Edwards Tilos Therapeutics Executive Chairman & Board Member 000 0000
Julius Knowles Ph.D Partners HealthCare Innovation Board Member 000 0000
Martin Heidecker Ph.D Boehringer Ingelheim Venture Fund Board Member 000 0000

2 Former Board Members

Tilos Therapeutics Former Investors (3)

To view Tilos Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
Partners Innovation Fund Venture Capital Minority 000 0000 000000 0
ShangPharma Innovation Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial